
Corp. Office : SM House, 11 Sahakar Road, Vile Parle (East), Mumbai - 400 057, Tel.: (+91-22) 6726 1000,
Fax: (+91-22) 6726 1067, Email : info@guficbio.com, Website: www.gufic.com

308/LG/SE/NOV/2025/GBSL

November 14, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400 001
Scrip Code: 509079

To,
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Symbol: GUFICBIO

Subject: Investor Presentation

Dear Sir/Madam,

Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Investor Presentation on Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025.

Kindly take the same on record.

Thanking You,

Yours truly,

For Gufic Biosciences Limited

Ami Shah
Company Secretary & Compliance Officer
Membership No. A39579

Encl.: As above



Investor Presentation
For Q2FY2025



This presentation has been prepared by and is the sole responsibility of **Gufic Biosciences Limited** (the “Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions.

This presentation does not constitute or form part of any offer or invitation or inducement to sell or issue, or any solicitation of any offer or recommendation to purchase or subscribe for, any securities of the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract or commitment thereof. In particular, this presentation is not intended to be a prospectus or offer document under the applicable laws of any jurisdiction, including India. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. There is no obligation to update, modify or amend this communication or to otherwise notify the recipient if the information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

Certain statements contained in this presentation that are not statements of historical fact constitute “forward-looking statements.” You can generally identify forward looking statements by terminology such as “aim”, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “objective”, “goal”, “plan”, “potential”, “project”, “pursue”, “shall”, “should”, “will”, “would”, or other words or phrases of similar import. These forward-looking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or other projections. Important factors that could cause actual results, performance or achievements to differ materially include, among others: (a) our ability to successfully implement our strategy, (b) our growth and expansion plans, (c) changes in regulatory norms applicable to the Company, (d) technological changes, (e) investment income, (f) cash flow projections, and (g) other risks.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes.



Q2 FY26 Business & Financial Highlights



Indore Facility update: Progress on track as planned

We have built one of the most advanced lyophilized injectable facilities, commenced production in October 2024

Designed for **WHO GMP, EU GMP, ANVISA, MHRA, and USFDA** standards, it houses:

- **Lyophilized vials** – 5 million/month
- **Liquid vials** – 6 million/month
- **Ampoules** – 10 million/month

Built for both **domestic and export markets**, it is purpose-engineered for complex injectable manufacturing.

In a highly regulated market, early-stage precision is critical to avoid long-term compliance risk. We are deliberately following a **stepwise qualification approach** to ensure *first-time-right* execution, full global audit readiness, and data-driven scaling.

Timeline of our phased approach

Milestone	Target	Status & Commentary
Installation & Operational Qualification (IQ/OQ)	October 2023	☑ Completed – facility meets WHO GMP, EU GMP, ANVISA, MHRA, USFDA design standards
Performance Qualification (PQ) All Lines & Utilities	Dec 2023 – Jun 2024	☑ Completed with multiple container trials; parameters locked
Media Fills (Aseptic Process Simulations)	Jul 2024 – Oct 2024	☑ Completed for all four lines; sterility validated
Product Permissions from State FDA	Ongoing	🌀 145 approvals received to date; more in pipeline
Tech Transfer for existing products from Navsari & Process Validation Batches for initial products	Oct 2024 – ongoing	🌀 Completed for 40 products; stability studies in progress. 27 more products under development
Vendor Audits Indian Pharma Majors	H1-FY26	🌀 18 completed, more lined up; CMO contracts commenced
30% Capacity Utilization	FY26	🌀 On-track
Global Regulatory Clearance		
EU GMP & UK MHRA	Q1-FY27	🌀 Preparations on track; facility documentation & processes audit-ready
US FDA	FY29	Dates will be triggered by our clients as Gufic will be a pure-play CDMO partner

Capitalized Q3 FY25 → 30% Utilization & Indore EBIDTA Breakeven FY26 → Margin Accretive State FY27



I. Hospital Injectable Platform. **Therapy Focus: Anti-Microbials, Immunology & Cardiac Critical Care**

A. Critical Care Cluster

Executing a hospital-focused strategy to scale coverage, deepen retention, and grow share in advanced critical-care injectables.

1. Expanding Hospital Footprint

- Broader penetration across tertiary, secondary & corporate chains
- High-engagement national scientific platforms driving new account access
- Priority segments: sepsis, resistant infections, invasive fungal disease

2. Strengthening Retention & Volume Share

- Multi-stakeholder engagement deepening trust & repeat usage
- KOL-led evidence shaping adoption of Thymosin Alpha & Dalbavancin

3. Building a High-Science Injectable Portfolio

- Advanced injectables across gram-positive, gram-negative & sepsis care
- Dalbavancin: once-weekly advantage drives share in corporate hospitals

4. Focused Execution

- Focused execution to grow molecule-class volume share in existing accounts
- Work on protocol integration into Standard Of Care for new launches to create runway for long-term demand

B. Sparsh

Building a hospital-centric platform in contrast media, nutrition, and cardiac critical care.

1. Deepening Share of the Hospital Wallet

- CMEs, pharmacist & nurse programs strengthen in-hospital equity and account depth.
- Differentiated formats (Dual Chamber Bags, S-Pantoprazole) validating commercial acceptance of our innovative launches.

2. Strengthening Access & Execution Infrastructure

- Field expansion and CFA-led distribution enabling better service, supply reliability & receivables control.
- Entry into high-value regions strengthens institutional footprint.

3. Readiness for a Multi-Category Scale Up


- Jan'26 Contrast Media launch expands TAM immediately.
- Apr'26 TPN launch positions Sparsh as a holistic critical-care partner.
- Cardiac critical-care portfolio development creates early leadership in an under-penetrated segment.




Complex injectable pipeline for the hospital platform

Drug Class	Unique Advantages	Complexity in Manufacturing
Novel β-lactam/β-lactamase Inhibitor Combo	Targets multi-drug resistant Gram-negative bacteria; highly effective for severe hospital-acquired infections.	Complex formulation with dual agents requires precise blending, stabilization, and maintaining consistent potency against multi-resistant bacteria.
Advanced Carbapenem Combination	Broad-spectrum efficacy against resistant Gram-negative pathogens, including carbapenem-resistant strains.	Manufacturing challenges include stabilizing multiple compounds while preserving individual activity and minimizing cross-reactivity to ensure therapeutic efficacy.
Next-Generation Echinocandin	Improved dosing interval and effectiveness against Candida and Aspergillus species in systemic infections.	Manufacturing complexity due to novel structure requiring stringent stability controls to prevent degradation and ensure high bioavailability.
Broad-Spectrum Tetracycline Derivative	Effective against both Gram-positive and Gram-negative organisms, including drug-resistant strains.	Dual formulation (tablet and injectable) necessitates specialized production processes to maintain bioavailability and potency for each form.
Acid-Stable Fluoroquinolone	Enhanced activity in acidic environments, ideal for tissue infections such as abscesses with lower pH.	Complex synthesis due to acid-stable structure; requires advanced stabilization methods for bioavailability across different formulations.
Siderophore-Cephalosporin	Targets resistant Gram-negative bacteria by utilizing an iron transport mechanism to penetrate bacterial cells.	Manufacturing complexity involves managing the molecule's chelating properties to maintain stability and targeted bacterial cell entry.
Respiratory-Targeted Fluoroquinolone	Broad effectiveness in respiratory and skin infections with enhanced activity against drug-resistant pathogens.	Stabilizing fluoroquinolone structure in tablet and injectable forms demands specialized manufacturing to maintain consistent potency and patient safety.

Domestic Business Breakup



Total Revenue Breakup





II. Women's Health Platform. Therapy Focus: Assisted Reproductive Technology(IVF), Immunology & Ortho-gynae

A. Fetricare Cluster

Building scientific leadership in advanced fertility injectables and reproductive immunology.

1. Owning the High-Science Fertility Conversation

- Extensive KOL participation across leading fertility forums for breakthrough immune therapy in recurrent implantation failure. Emerging as the category leader in this niche unmet therapy area.
- Pan-India International Speaker Program (Dr. Gil Mor – Ex President of ASRM) cements thought-leadership in reproductive immunology.

2. Scaling Specialist Engagement & Brand Momentum

- Multi-city roadshows expanding reach across key IVF hubs.
- Strong YTD performance (>50% YoY growth) with power brands delivering high double digit growth.
- Portfolio mix improved towards high end hormones

3. Preparing for a Rich Innovation Cycle

- r-FSH and vaginal microbiome products as near-term scientific triggers.

4. Outlook for Power brands:

- Puregraf – On track to become ~INR 25 crore pa brand
- Cetrocare – On track to break into top 3 for the molecule segment
- Supergraf – Launched in 2024, target to become INR 15 crs brand in 2 years
- Guficin Alpha – Target to become an INR 10 crore brand

B. Zenova

Scaling a stable, specialty-focused women's health & ortho platform.

1. Deepening Scientific & Patient-Centric Engagement

- CMEs, RTMs and regional/national conferences strengthening specialist advocacy.
- 300+ awareness programs building visibility right at the point of care.

2. Consistent, High-Quality Execution

- Strong double digit YoY growth across Q2.

3. Building a Pipeline for Category Leadership

- Fertiforce & Polmaxib-P showing strong early adoption.
- Rich pipeline in endometriosis, PCOS, menopause and pain to drive multi-year growth.
- Cannabis- and exosome-based innovations enhance future differentiation

4. Improved Product Mix

- Prescription-led transition: Rx-to-injectables ratio continues to improve now at 70:30.
- DD1 & Strenail driving the QoQ growth – reaffirmed as Zenova's flagship brands.



III. Botulinum Toxin Platform. **Therapy Focus: Aesthetics & Neurology**

A. Aesthaderm

Evolving from toxin leadership into a full-stack aesthetics ecosystem.

1. Accelerating Multi-Category Portfolio Expansion

- Global in-licensing progress in fillers & biostimulators.
- Early evidence generation strengthens Stunnox before full-stack launch.

2. Building a Scalable Clinician-Development Engine

- GROW Symposium, cadaver labs & hands-on workshops creating repeatable training infrastructure.
- Rapid expansion in Tier-1/2 centres; 1,000+ practitioners recommending Stunnox.

3. Unlocking the Next Growth Curve

- Focus on chain-clinic entry with published data and KOL feedbacks
- Fillers/boosters expected to create TAM expansion and accelerate the growth path.

B. Neurocare

Scaling the Therapeutic Toxin Franchise Through Injector Creation & Category Expansion

1. Building the Standard-of-Care Toxin Platform

- A single-product, high-science franchise with deep specialisation → high clinician trust → high lifetime value per injector. Focused on guideline-backed neurological & neuromuscular indications
- Continued expansion of injector base will drive compounding, long-term revenue due to high repeatability and chronic-use patterns

2. Creating New Injectors & Expanding the Universe

- Master the Toxin, PG programs, hands-on workshops
- Clinic staff training enables safe in-clinic handling & adoption
- Scientific data generation → stronger adoption

3. Scaling Category Leadership & Future Pipeline

- Expanding into Urology, Ophthalmology, Pain & Neurosurgery
- Focus on “hero indications”: post-stroke spasticity & cerebral palsy
- All-time-high monthly sales; strong YTD vial momentum

IV. Nutra, Ayurveda & Others. Therapy Focus: Chronic Musculoskeletal Pain & Gastro

Healthcare

Creating a science-backed, modern Ayurvedic & musculoskeletal care franchise.

1. Strengthening Scientific Foundations in Ayurveda

- Online and offline educational engagements building credibility and next-gen practitioner loyalty.
- Specialty engagement across ortho & Ayurveda supporting evidence-led positioning.

2. Driving Community-Led Patient Flow

- Nationwide gout, arthritis & osteoporosis detection camps enhancing patient pull.
- Awareness initiatives deepening brand recall and therapy-level relevance.

3. Expanding a Differentiated, High-Value Portfolio

- Cannabis-based formulations gaining traction; further upgrades in pipeline.
- Entry into GI with Vonoprazan broadens reach into fast-growing segments.
- Operational optimisation supports profitable mid-teens growth.





V. CMO & International Business: *Converting complex injectables expertise into a global sales and licensing engine.*

RA Status--> Key Products with Stringent Countries-Ready Dossiers

Molecule	Therapeutic class	Regulated Market Dossier Readiness	Current Market Size (US\$Mn)
1	PPI with high acid suppression stability	☑	207.4
2	PPI with broad ulcer management use	☑	176.8
3	Glycopeptide gold standard for MRSA coverage	☑	176
4	Long-acting glycopeptide for Gram-positive coverage	☑	104.7
5	Next-gen glycyclcycline for multi-drug resistant infections	☑	104.2
6	Macrolide and respiratory infection role	☑	34.4
7	Long-acting macrolide with extended tissue penetration	☑	16.9
8	Cornerstone TB agent	☑	3.7
Total (Select countries in EU, LATAM & ROW)			824.1

Strategic Roadmap (3–5 Years)

- **Market Share Goal:** Capture **5–10%** in identified geographies
- **Portfolio Expansion:** Build on current high-value molecules, adding new products from Indore

Manufacturing & Capacity Alignment

- **Current Production:** EU-GMP **Unit II (Navsari)**
- **Next Phase:** Scale-up at **Indore facility** will de-bottleneck Navsari & add new products to portfolio

Operational Leverage

- **Capacity Unlock:** Tech transfer to Indore + domestic CMO shift → frees Navsari for exports
- **Export Growth:** Volumes already ramping as Navsari capacity opens up

Strengthening the Global Partnering Model

- A major global health organization has partnered with us on one of our most complex injectable assets, providing access to 109 public health markets worldwide
- Strong deal flow across Turkey, Brazil and India (for US market) via out-licensing and tech transfer.

Gufic Ireland secured its 1st Marketing Authorization in the EU. This gives Gufic direct access to EU markets.

In the current quarter, we have filed 2 of these products in 18 EU countries. In H1 secured **24 key product and facility approvals** across South Africa, Columbia, Portugal, Myanmar, Sri Lanka, Cambodia, Thailand, and Lithuania, bolstering our regulatory footprint in critical care, gastro, and anti-infectives.



Update on R&D

- **Peptides R&D:** Paving the Way for In-house Critical API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader vision of internalizing the production of critical APIs. This strategic move reinforces our commitment to self-reliance and robust supply chains
- **Innovative Dual Chamber Syringes:** Elevating Drug Delivery Systems: Our dedicated efforts have led to the development of a wide array of products within the new drug delivery system of Dual Chamber Syringes. This innovation ensures streamlined reconstitution, precise dosing, and sustained sterility, bridging the gap from plant to patient.
- **API Research Development:** Fostering Therapeutic Advancements: At Navsari, our API Research Development has achieved noteworthy milestones in therapeutic categories including Antifungal, Anticoagulant, Tetracycline Antibiotics, Progestin, Beta 3 Adrenergic Agonists, Antidiabetic, and Cyclopeptide Hormones. Our development projects remain steadfastly aligned with our strategic plan, driving us toward pioneering advancements in these critical therapeutic areas.

Update on Selvax

Developing SVX-3001 (humanized anti-CD40 agonist antibody) co-administered intratumorally with IL-2 to amplify anti-tumour immune response while minimizing systemic toxicity

Unique Immunotherapy Approach

- Targets CD40 to “convert” immunologically “cold” tumours into “hot” tumours, improving immune cell infiltration and long-term tumour regression
- Demonstrated >80% clearance and abscopal (distant tumour) effects in preclinical mesothelioma models

Preclinical Efficacy

- Broad efficacy across eight solid tumour types in mouse models (cure rates 22–93%)
- Superior to standard-of-care FOLFIRINOX in pancreatic adenocarcinoma models (100% cure vs. 0%)

Canine Clinical Proof-of-Concept


- Phase I trial in dogs with soft-tissue sarcomas: 68.4% clinical benefit rate (25% complete remission, 42% stable disease) with minimal grade 1–2 adverse events

Pipeline & Next Steps


- SVX-1001 (murine model studies) completed
- SVX-2001 (canine antibody) commercialization arm established
- SVX-3001 (humanized antibody) advanced cell-line development; IP filed and entering international patent phase S




Strategic Initiatives that will further amplify growth over the next few years



Increase in overall market and market share in Botulinum Toxin range of products through introduction of fast acting injectable and topical formulation (first in India and world)



Leverage new biological technology platform to develop preventive and curative medical care for fatal viral infections



Commercialization of immuno-oncology therapy

Increase market share in contract manufacturing beyond paranterals to other drug delivery systems



Profit & Loss Statement

Particulars (in Rs. Crore)	Q2 FY26	Q1 FY26	Q2 FY25	H1 FY26	H1 FY25
Total Revenue	230.4	226.9	204.2	457.3	407
EBITDA	37.9	33.2	38.7	71.1	75.8
EBITDA Margin %	16.45%	14.63%	18.95%	15.55%	18.62%
Profit before Tax	20.5	16.3	29.3	36.8	57.4
PBT Margins %	8.90%	7.18%	14.35%	8.05%	14.10%
Tax	5.6	4.2	7.5	9.8	14.7
Profit After Tax	14.9	12.1	21.8	27	42.6
PAT Margin %	6.47%	5.32%	10.68%	5.90%	10.47%




Company Overview



Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals
Nutraceuticals, Natural Herbal products

One of the **Largest Manufacturers of Lyophilized Injections**
in India with a wide range of products in various therapy areas



Moving in the right direction...with a well-defined business structure



World Class Manufacturing Infrastructure

Unit - I at Navsari

Botulinum Toxin Facility
Lyophilized/Powder Injectables Facility
Natural Products (Topical/Liquid)
API Facility

Capacities

- ✓ Lyophilized – 18 mn vials p.a.
 - ✓ Ampoule – 12mn p.a.
- ✓ Ointment – 6mn tubes p.a.
- ✓ Lotion – 6mn bottles p.a.
- ✓ Syrup – 6mn bottles p.a.
 - ✓ PFS – 2.8mn PFS p.a.

Unit - II at Navsari

Lyophilized Injectables Facility
Capability to manufacture Liposomal
Amphotericin B and Depot Injections

Capacities

- ✓ Lyophilized – 30mn vials p.a.
 - ✓ PFS – 30mn PFS p.a.

Gufic - Belgaum

Natural Products Facility

Capacities

- ✓ 60mn capsules p.a.
- ✓ 3.6mn powder p.a.

**WHO GMP, Philippines BFAD, Nigeria NAFDAC, Cambodia MOH, Kenya PPB,
Ethiopia FMHACA, Thailand MOH, Sri Lanka NMRA**

**EU GMP (Hungary), ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP,
Australia TGA, Colombia INVIMA, Uganda NDA, SAHPRA South Africa**



New Manufacturing Infrastructure

Unit - III at Indore

Lyophilized/Powder Injectables
Facility

Capability to cater to regulated
markets such as US & EU

Capacities

- ✓ Lyophilized Inj – 60 mn vials p.a.
- ✓ Liquid Inj (Ampoules) – 120mn p.a.
- ✓ Liquid Inj (Vials) – 72 mn units p.a.

Penem Block

Dedicated facility for Penem
Carbapenems (Lyophilized / Dry
Powder Inj / Oral Solids / Dual
Chamber Bags)

Capacities

- ✓ Lyophilized – 3mn vials p.a.
- ✓ Dual Chamber Bags 2.4 mn IV bags
- ✓ Dry Powder Inj 30 mn Vials

UPDATE ON CAPEX

Indore

Commercial Production Achieved

From Build to Benchmark



Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari

**Prime
Bio**


GUFIC
G R O U P

➤ Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation

➤ Gufic is equipped with all the necessary analytical testing procedures for safety and efficacy of Botulinum toxin

➤ Gufic and Prime bio, to develop several innovative formulations with Botulinum toxin in the field Dermatology, Neurology and Pain Management





Consolidating the Domestic Branded Business

Products

100+

SKU's

200+

Prescribers

30,000+

Retail Reach

1,10,000+

Doctors Reach

1,20,000+

Hospital Coverage

- 80 % of Tertiary care,
- Presence in Government Institutions

CRITICAL CARE



- Field Force: 250
- Therapy Areas: Antibacterial, Antifungal, Pain Management, Blood products, GI Immuno modulator

INFERTILITY



- Field Force: >150
- Therapy Areas: Hormones, Recombinant Products, Infertility Supplements

MASS SPECIALITY



- Field Force: >180
- Therapy Areas: Anti Infectives, Gastro, Gynaecology, Respiratory, Nutraceuticals, Dermaology

NATURAL AND NUTRACEUTICAL PRODUCTS



- Field Force: >300
- Therapy Areas: Bone Health, Pain Management, Immunity, Gastro, Stress, Nutraceuticals, Wound care, Respiratory, Gynaec

ORTHO – GYNAEC PRODUCTS



- Field Force: >60
- Therapy Areas: Bone Health, Pain Management, Fractures, Arthritis, Pregnancy, Post Menopausal

DERMO – COSMECTICS PRODUCTS



- Field Force: >40
- Therapy Areas: Neurotoxin, Emollients, Antiaging, Cleansers, Pre & Post Procedure, Hyperpigmentation, Sunscreens

Venturing into new futuristic therapy areas : **Biologicals and Immuno-Oncology**



Expanding Creditability in CMO Business

Offer CMO services
for **India and
Global Markets**

70+
Companies

150+ Products
across multiple therapy areas

Reliable CMO service for
**quality products over a
decade**

One of the Largest Supplier of Formulations

Doxycycline

Tigecycline

Gonadotropins

Liposomal
Amphotericin B

Micafungin

Remdesivir

OUR ESTEEMED PARTNERS



Abbott



SERUM INSTITUTE OF INDIA
Cyrus Poonawalla Group



**FRESENIUS
KABI**
caring for life



Biocon



LUPIN



**SUN
PHARMA**



HETERO

Cipla



Emcure
SUCCESS THROUGH INNOVATION

Zydus
dedicated to life

CORONA
Remedies
Inspiring Quality Life...

FERRING
PHARMACEUTICALS

Dr.Reddy's

WOCKHARDT

Koyé
Health. Happiness.

glenmark
A new way for a new world



Expanding Geographical Reach



130+ Products registered globally (in 15+ countries)



150+ Products in pipeline for registration (in 30+ countries)

CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO
ALGERIA | DOMINICAN REPUBLIC | VENEZUELA | SUDAN | ETHIOPIA | ECUADOR | PERU | PARAGUAY | NIGERIA | SOUTH AFRICA | EGYPT
ZIMBABWE | UGANDA | YEMEN | SRI LANKA | MYANMAR | PHILIPPINES | THAILAND | CAMBODIA | VIETNAM | MALAYSIA | UKRAINE
JORDAN | SYRIA | GEORGIA | UZBEKISTAN | KAZAKHSTAN | NEPAL | RUSSIA | AUSTRALIA



Building API Capabilities

Special Facility dedicated to API


Focused on developing non infringing, novel, cost effective and scalable chemical process for APIs, Peptides and Cyclopeptides

The categories of API's manufactured are antifungals, antibacterial, anesthetics and intermediates for antifungals



Presence in **25** countries worldwide

70 customers PAN India





Strong Partnership & Licensing Deals



European leader in IV drug delivery systems. Collaborated with Gufic to launch Dual Chamber Bags for the 1st time in India for anti - infectives

Through our collaborations with global partners that are researching to expand the frontiers of pharma and biotechnology, Gufic will be a technology bridge to the future of healthcare and economical patient care in India



Therapy Area: Toxins

Strain transfer, Tech transfer, formulation development and manufacturing at Gufic



Therapy Area: Recombinant products and Anti Infectives

Collaboration on several API to develop new product



Therapy Area: Infertility

Tech transfer and Clinical development(Phase III) of the product at Gufic



Therapy Area: Dermo Cosmetics

Technical collaboration and Product Development



Extensive Sales, Distribution IT Infrastructure in India

2 Central Warehouses
located in North Delhi and
West Bhiwandi



23 Carrying & Forwarding
(C&F) agents across India



1,200+ Stockists for
effective distribution across
India



IT Infrastructure

- Integrated IT Systems with Sales and Distribution Infrastructure
- SAP S4 HANA (being Implemented) across all Departments
- Tablets, Sales Force Automation and Effectiveness tools in place

Pan India Presence with a
field force of **1,000+**



Retail coverage of more than
1,10,000 retailers



Doctors Reach of
1,20,000+



Growth Levers

1

INDIA BUSINESS

- Consolidation of the Critical Care Infertility business
- Entry into new therapy areas Dermatology - Aesthaderm
- Strategic focus on Healthcare division with entry into Ortho Gynecology products through a new division Stellar
- Build a robust pipeline of new products
- Build up the licensing products portfolio

2

INTERNATIONAL BUSINESS

- Expand our presence in regulated markets such as US EU
- Gradually commercialize the pipeline products
- Explore newer geographical locations

3

CMO BUSINESS

- Scale up the manufacturing capacity
- Consolidation of the clients offer more products to existing clients
- Expand the customer base
- New product offerings



Our Robust R&D and Clinical team to augment growth

Research & Development (R&D)

State-of-the-art R&D Facility in Navsari, Gujarat with expertise in

- Formulation Development
- Technology Transfer
- API Development

Patents in various therapy areas

- Granted: 5
- Filed/In-process of filling : 8

Major Projects in Pipeline

50+ across all therapy areas

- Anti Infectives: 11
- Dermatology: 7
- Gynaec: 6
- CNS: 4
- Anti Fungal: 3
- Oncology: 3

Special / NDDS Projects

- Innovative formulations of Botulinum Toxin
- Liposomal Amphotericin-B Injection
- Depot Injection
- Dual Chamber IV Bags
- Dual Chamber Syringes

Clinical Team



Strong Clinical team comprising of

- Medical
- Regulatory
- Product Development

Projects in various Clinical Phases

- Ongoing: 5
- Pipeline: 12

Capabilities to take
Synthetic and Biological
Projects across Phase II and
Phase III clinical trials

Pharmacovigilance Team

Historical Financials



Historical Financials

Particulars (Rs. Crs.)	H1 FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Total Revenue	457.3	823.4	808.8	693.2	782.3	491.4	384.6	359.5
EBITDA	71.1	140	149.5	137.2	151.1	87.7	57.9	56.7
EBITDA Margin %	15.55%	17.00%	18.48%	19.79%	19.31%	17.85%	15.05%	15.77%
Profit before Tax	36.8	94.4	115.7	106.7	126.8	57.7	30.1	40.2
PBT Margin %	8.05%	11.46%	14.31%	15.39%	16.21%	11.74%	7.83%	11.18%
Tax	9.8	24.5	29.5	27	31	13.5	7.4	13.4
Profit After Tax	27	69.9	86.2	79.7	95.8	44.2	22.7	26.8
PAT Margin %	5.90%	8.49%	10.66%	11.50%	12.25%	8.99%	5.90%	7.45%



Historical Balance Sheet (Equity & Liabilities)

EQUITY & LIABILITIES (Rs. Crs.)	Sep-25	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Equity Share Capital	10	10	10	9.7	9.7	9.7	9.7	7.8
Other Equity	618.5	591.3	522.5	338.1	259.4	163.7	119.6	67.6
Total Equity	628.5	601.3	532.5	347.8	269.1	173.4	129.3	75.4
Non-Current Liabilities								
Financial Liabilities								
i. Borrowings	117.83	130.5	153.9	190.7	48	35.4	19.5	11.3
ii. Other Financial Liabilities	5.62	5.4	5	5	5	5	4.7	4.7
iii. Lease Liability	16.24	19.6	11.6	16.2	0.3	2.8	6.2	0
Provisions	18.78	17.5	15.4	13.3	12.4	10.2	7.9	1.9
Deferred Tax Liabilities (net)	11.80	7.8	2.1	0	0.2	1.5	0	0
Total Non-Current Liabilities	170.27	180.80	188.00	225.20	65.90	54.90	38.30	17.90
Financial Liabilities								
i. Borrowings	228.6	179.9	163.1	120.7	13.3	16.3	93.1	84.7
ii. Trade Payables								
Total outstanding dues of micro enterprises and small enterprises	6.6	2.2	2.3	9.8	7	3.9	0	0
Total outstanding dues of other than micro enterprises & small enterprises	192.3	156.5	163.9	120.5	134	109.2	117.1	89.7
iii. Other Financial Liabilities	17.0	15.2	13.7	10.8	11.4	15.3	10.8	12.5
iv. Lease Liability	6.5	6.2	4.3	6.6	2.8	3.4	3.4	0
Provisions	4.5	4.4	4.7	4.2	4.9	4.6	6.6	3.4
Other current Liabilities	14.1	23.1	17.4	12.5	12.4	9.5	8.7	7.3
Current Tax Liabilities (net)	-	-	2.5	3.1	0.7	1.6	0	3.1
Total Current Liabilities	469.6	387.5	371.9	288.2	186.5	163.8	239.7	200.7
TOTAL EQUITY & LIABILITIES	1268.4	1169.6	1092.4	861.2	521.5	392.1	407.3	294.0



Historical Balance Sheet (Assets)

ASSETS (Rs. Crs.)	Sep-25	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21	Mar-20	Mar-19
Non-Current Assets								
Property, plant and equipment	467.6	475.2	138.3	126.8	105.5	93.8	72.7	70.3
Intangible assets	6.3	6.3	5.6	0.7	0.6	0.4	0.6	0.4
Capital work-in-progress	24.0	21.8	307.1	169.6	40.9	13.4	30.6	9.6
Right of use assets	21.1	24.5	14.9	32.1	9.1	5.8	9.3	0
Financial Assets								
i. Investments	2.9	2.8	1.8	0.8	0	0	0	0
ii. Loans	0.8	0.2	0.4	0.3	0.2	0.3	10.3	4.2
iii. Other financial assets	10.6	9.7	8.9	8.1	9.1	11.3	0	3.8
Deferred tax assets (net)	0.0	0	0	1	0	0	0.6	0.7
Other non-current assets	11.7	5.3	15.05	57.7	35.3	6.5	10.1	5
Total Non Current Assets	545.0	545.8	492.05	397.1	200.7	131.5	134.2	94
Current Assets								
Inventories	229.7	216.9	200.5	183.5	115.6	94.4	122.5	114.2
Financial Assets								
i. Trade Receivables	320.9	314.6	329.9	205.5	151.6	124.5	107	96.7
ii. Cash and cash equivalent	73.6	14.9	1.1	28.6	11.6	6.2	4.3	3.9
iii. Bank balances	13.5	13.3	12.3	18.1	15	7	12.1	8.7
iv. Loans	0.7	0.3	0.3	0.2	0.4	0.3	0.3	0.1
Current Tax assets (Net)	82.5	1.6	0	0	0	0	0	0
Other current assets	2.6	62.2	56.2	28.3	26.7	28.2	27.2	22.5
Total Current Assets	723.5	623.8	600.3	464.2	320.9	260.6	273.4	246.1
TOTAL ASSETS	1268.4	1169.6	1092.4	861.3	521.6	392.1	407.6	340.1



Historical Cash Flows

Cash Flow Statement (Rs. Crs.)	H1 FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19
Net Profit Before Tax	36.8	94.4	115.7	106.7	126.9	57.7	30.1	35.3
Adjustments for: Non - Cash Items / Other Investment or Financial Items	33.5	43.8	34.1	29.6	23.2	30.8	24.7	13.4
Operating profit before working capital changes	70.3	138.2	149.8	136.3	150.1	88.5	54.8	48.7
Changes in working capital	-4.4	7.4	-130.2	-135.3	-10.7	10	2.5	-33.5
Cash generated from Operations	65.9	145.6	19.6	1	139.4	98.5	57.3	15.2
Direct taxes paid (net of refund)	-6.8	-22.8	-27	-27.7	-33.1	-9.4	-10.1	-10
Net Cash from Operating Activities	59.1	122.8	-7.4	-26.7	106.3	89.1	47.2	5.2
Net Cash from Investing Activities	-15.4	-71.8	-102.4	-190.7	-94.6	-8.5	-42.5	-13
Net Cash from Financing Activities	15	-37.2	82.4	234.3	-6.2	-78.6	-4.2	7.7
Net Decrease in Cash and Cash equivalents	58.7	13.8	-27.4	16.9	5.5	2	0.5	-0.1
Add: Cash & Cash equivalents at the beginning of the period	14.9	1.1	28.6	11.6	6.2	4.3	3.9	3.7
Cash & Cash equivalents at the end of the period	73.6	14.9	1.2	28.5	11.7	6.3	4.4	3.6



THANK YOU

Company: Gufic Biosciences Limited

CIN: L24100MH1984PLC033519

Mr. Avik Das – Investor Relations

avik.das@guficbio.com

Tel: +91 22 67261000